Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MADHAVI AMPAJWALA

Allopathic & Osteopathic Physicians Family Medicine

NPI
1457471419
CMS profile
1145338
Location
FRISCO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$1,272.81

68 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,256.16 67
Entertainment $16.65 1

By paying entity

PY2024 · entire year · sorted by reported total

Page 2 of 2; records 51–68 of 68 matching records. This page contains 18 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MADHAVI AMPAJWALA

NPI 1457471419 · CMS profile ID 1145338

Allopathic & Osteopathic Physicians / Family Medicine

FRISCO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–68 of 68 matching records. This page contains 18 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1457471419?year=2024&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MADHAVI AMPAJWALA, NPI 1457471419, CMS profile ID 1145338. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–68 of 68 matching records. This page contains 18 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1457471419?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). MADHAVI AMPAJWALA, NPI 1457471419, CMS profile ID 1145338. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–68 of 68 matching records. This page contains 18 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1457471419?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
MADHAVI AMPAJWALA, NPI 1457471419, CMS profile ID 1145338, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–68 of 68 matching records. This page contains 18 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1457471419?year=2024&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

68 matching records · $1,272.81 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 68 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–68 of 68.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
IDORSIA PHARMACEUTICALS US INC $16.1103/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1146773680 CMS
Novo Nordisk Inc $17.3303/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1097159934 CMS
Amgen Inc. $14.5803/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117190047 CMS
Inari Medical, Inc. $27.6503/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1140057930 CMS
PFIZER INC. $10.2303/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131211517 CMS
Novo Nordisk Inc $21.4002/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1097510702 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $24.2102/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118016974 CMS
Itamar Medical Inc $14.9702/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1153392434 CMS
PFIZER INC. $14.9802/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131052228 CMS
Abbott Laboratories $21.4002/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1125074884 CMS
Lilly USA, LLC $19.7401/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135151816 CMS
AstraZeneca Pharmaceuticals LP $29.9501/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104668535 CMS
Lilly USA, LLC $15.9101/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135162069 CMS
ABBVIE INC. $32.5101/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103220675 CMS
Amgen Inc. $13.6401/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1111516759 CMS
Novo Nordisk Inc $16.2301/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1097740621 CMS
Exact Sciences Corporation $25.8801/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114576133 CMS
Optos, Inc. $16.6501/09/2024 Entertainment No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141500728 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,258.64 81
PY2020 $270.87 18
PY2021 $507.02 30
PY2022 $1,086.85 60
PY2023 $1,241.77 71
PY2024 $1,272.81 68
PY2025 $1,510.90 69

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $609,243.09 64
PY2024 Principal investigator $1,262,008.52 75
PY2023 Principal investigator $2,228,791.68 154
PY2022 Recipient $532.00 1
PY2022 Principal investigator $5,664,352.98 159
PY2021 Principal investigator $2,677,482.07 50
PY2020 Principal investigator $74,582.74 44
PY2019 Principal investigator $691,001.22 55

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

64 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ModernaTX, Inc. $3,000.00 12/12/2025 Non-covered Recipient Entity
MARWAH INVESTMENTS CORPORATION
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252969309
Principal investigator 1 ModernaTX, Inc. $91.00 12/12/2025 Non-covered Recipient Entity
MARWAH INVESTMENTS CORPORATION
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252969357
Principal investigator 1 ModernaTX, Inc. $7,761.00 11/21/2025 Non-covered Recipient Entity
MARWAH INVESTMENTS CORPORATION
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252969333
Principal investigator 1 ModernaTX, Inc. $57,368.28 11/14/2025 Non-covered Recipient Entity
MARWAH INVESTMENTS CORPORATION
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252969339
Principal investigator 1 ModernaTX, Inc. $3,516.50 10/22/2025 Non-covered Recipient Entity
MARWAH INVESTMENTS CORPORATION
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252969399
Principal investigator 1 PFIZER INC. $3,661.88 10/07/2025 Non-covered Recipient Entity
Marwah Investments Corporation dba ACRC Trials
A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VACCINE CANDIDATES IN HEALTHY CHILDREN No dispute reported 06/30/2026 1228824646
Principal investigator 1 ModernaTX, Inc. $1,000.00 09/24/2025 Non-covered Recipient Entity
MARWAH INVESTMENTS CORPORATION
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252969337
Principal investigator 1 ModernaTX, Inc. $3,500.00 09/24/2025 Non-covered Recipient Entity
MARWAH INVESTMENTS CORPORATION
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252969363
Principal investigator 1 ModernaTX, Inc. $1,500.00 09/24/2025 Non-covered Recipient Entity
MARWAH INVESTMENTS CORPORATION
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252969367
Principal investigator 1 ModernaTX, Inc. $973.54 09/24/2025 Non-covered Recipient Entity
MARWAH INVESTMENTS CORPORATION
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252969369
Principal investigator 1 ModernaTX, Inc. $8,284.90 09/19/2025 Non-covered Recipient Entity
MARWAH INVESTMENTS CORPORATION
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252969379
Principal investigator 1 ModernaTX, Inc. $3,840.75 09/12/2025 Non-covered Recipient Entity
MARWAH INVESTMENTS CORPORATION
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252969311
Principal investigator 1 PFIZER INC. $5,126.64 08/23/2025 Non-covered Recipient Entity
Marwah Investments Corporation dba ACRC Trials
A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VACCINE CANDIDATES IN HEALTHY CHILDREN No dispute reported 06/30/2026 1228831172
Principal investigator 1 ModernaTX, Inc. $8,599.50 08/22/2025 Non-covered Recipient Entity
MARWAH INVESTMENTS CORPORATION
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252969323
Principal investigator 1 ModernaTX, Inc. $1,755.00 08/22/2025 Non-covered Recipient Entity
MARWAH INVESTMENTS CORPORATION
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252969365
Principal investigator 1 GlaxoSmithKline, LLC. $2,600.00 08/20/2025 Non-covered Recipient Entity
MARWAH INVESTMENTS CORP DBA ACR
A PHASE III, OPEN-LABEL, RANDOMIZED, CONTROLLED, MULTI-COUNTRY STUDY T No dispute reported 06/30/2026 1192168422
Principal investigator 1 ModernaTX, Inc. $2,727.00 08/20/2025 Non-covered Recipient Entity
MARWAH INVESTMENTS CORPORATION
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252969381
Principal investigator 1 ModernaTX, Inc. $3,034.20 07/25/2025 Non-covered Recipient Entity
MARWAH INVESTMENTS CORPORATION
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252969359
Principal investigator 1 ModernaTX, Inc. $250.00 07/25/2025 Non-covered Recipient Entity
MARWAH INVESTMENTS CORPORATION
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252969373
Principal investigator 1 PFIZER INC. $7,144.88 07/25/2025 Non-covered Recipient Entity
Marwah Investments Corporation dba ACRC Trials
A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VACCINE CANDIDATES IN HEALTHY CHILDREN No dispute reported 06/30/2026 1228830621
Principal investigator 1 ModernaTX, Inc. $21,411.00 07/18/2025 Non-covered Recipient Entity
MARWAH INVESTMENTS CORPORATION
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252969315
Principal investigator 1 ModernaTX, Inc. $10,370.10 07/18/2025 Non-covered Recipient Entity
MARWAH INVESTMENTS CORPORATION
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252969327
Principal investigator 1 PFIZER INC. $4,799.26 07/16/2025 Non-covered Recipient Entity
Marwah Investments Corporation dba ACRC Trials
A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VACCINE CANDIDATES IN HEALTHY CHILDREN No dispute reported 06/30/2026 1228830627
Principal investigator 1 ModernaTX, Inc. $3,000.00 07/07/2025 Non-covered Recipient Entity
MARWAH INVESTMENTS CORPORATION
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252969397
Principal investigator 1 ModernaTX, Inc. $607.50 06/25/2025 Non-covered Recipient Entity
MARWAH INVESTMENTS CORPORATION
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252969317
Principal investigator 1 ModernaTX, Inc. $245.00 06/25/2025 Non-covered Recipient Entity
MARWAH INVESTMENTS CORPORATION
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252969329
Principal investigator 1 PFIZER INC. $4,316.84 06/21/2025 Non-covered Recipient Entity
Marwah Investments Corporation dba ACRC Trials
A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VACCINE CANDIDATES IN HEALTHY CHILDREN No dispute reported 06/30/2026 1228829298
Principal investigator 1 ModernaTX, Inc. $11,362.00 06/18/2025 Non-covered Recipient Entity
MARWAH INVESTMENTS CORPORATION
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252969361
Principal investigator 1 ModernaTX, Inc. $13,716.00 06/06/2025 Non-covered Recipient Entity
MARWAH INVESTMENTS CORPORATION
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252969383
Principal investigator 1 ModernaTX, Inc. $14,850.00 06/04/2025 Non-covered Recipient Entity
MARWAH INVESTMENTS CORPORATION
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252969345
Principal investigator 1 ModernaTX, Inc. $28,304.00 06/04/2025 Non-covered Recipient Entity
MARWAH INVESTMENTS CORPORATION
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252969391
Principal investigator 1 ModernaTX, Inc. $573.28 06/04/2025 Non-covered Recipient Entity
MARWAH INVESTMENTS CORPORATION
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252969395
Principal investigator 1 PFIZER INC. $1,029.38 06/04/2025 Non-covered Recipient Entity
Marwah Investments Corporation dba ACRC Trials
A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VACCINE CANDIDATES IN HEALTHY CHILDREN No dispute reported 06/30/2026 1228829377
Principal investigator 1 PFIZER INC. $17,659.26 05/29/2025 Non-covered Recipient Entity
Marwah Investments Corporation dba ACRC Trials
A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VACCINE CANDIDATES IN HEALTHY CHILDREN No dispute reported 06/30/2026 1228833089
Principal investigator 1 ModernaTX, Inc. $5,352.75 05/28/2025 Non-covered Recipient Entity
MARWAH INVESTMENTS CORPORATION
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252969385
Principal investigator 1 ModernaTX, Inc. $13,067.60 05/21/2025 Non-covered Recipient Entity
MARWAH INVESTMENTS CORPORATION
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252969325
Principal investigator 1 ModernaTX, Inc. $2,657.20 05/16/2025 Non-covered Recipient Entity
MARWAH INVESTMENTS CORPORATION
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252969393
Principal investigator 1 GlaxoSmithKline, LLC. $6,900.00 05/09/2025 Non-covered Recipient Entity
MARWAH INVESTMENTS CORP DBA ACR
A PHASE III, OPEN-LABEL, RANDOMIZED, CONTROLLED, MULTI-COUNTRY STUDY T No dispute reported 06/30/2026 1192168402
Principal investigator 1 ModernaTX, Inc. $88,870.59 05/07/2025 Non-covered Recipient Entity
MARWAH INVESTMENTS CORPORATION
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252969313
Principal investigator 1 ModernaTX, Inc. $5,493.80 04/18/2025 Non-covered Recipient Entity
MARWAH INVESTMENTS CORPORATION
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252969331
Principal investigator 1 PFIZER INC. $29,256.64 04/15/2025 Non-covered Recipient Entity
Marwah Investments Corporation dba ACRC Trials
A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VACCINE CANDIDATES IN HEALTHY CHILDREN No dispute reported 06/30/2026 1228831813
Principal investigator 1 GlaxoSmithKline, LLC. $26,653.00 04/11/2025 Non-covered Recipient Entity
MARWAH INVESTMENTS CORP DBA ACR
A PHASE III, OPEN-LABEL, RANDOMIZED, CONTROLLED, MULTI-COUNTRY STUDY T No dispute reported 06/30/2026 1192168426
Principal investigator 1 GlaxoSmithKline, LLC. $1,087.90 04/02/2025 Non-covered Recipient Entity
MARWAH INVESTMENTS CORP DBA ACR
A PHASE III, OPEN-LABEL, RANDOMIZED, CONTROLLED, MULTI-COUNTRY STUDY T No dispute reported 06/30/2026 1192168399
Principal investigator 1 ModernaTX, Inc. $4,150.00 04/02/2025 Non-covered Recipient Entity
MARWAH INVESTMENTS CORPORATION
A Study to Evaluate the Safety and Immunogenicity of the mRNA COVID-19 Vaccines in Healthy Children Between 6 Months to Less Than 6 Years of Age No dispute reported 06/30/2026 1252969341
Principal investigator 1 ModernaTX, Inc. $1,920.00 04/02/2025 Non-covered Recipient Entity
MARWAH INVESTMENTS CORPORATION
A Study to Evaluate the Safety and Immunogenicity of the mRNA COVID-19 Vaccines in Healthy Children Between 6 Months to Less Than 6 Years of Age No dispute reported 06/30/2026 1252969371
Principal investigator 1 ModernaTX, Inc. $11,238.50 04/01/2025 Non-covered Recipient Entity
MARWAH INVESTMENTS CORPORATION
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252969343
Principal investigator 1 ModernaTX, Inc. $2,657.20 03/26/2025 Non-covered Recipient Entity
MARWAH INVESTMENTS CORPORATION
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252969401
Principal investigator 1 ModernaTX, Inc. $1,300.00 03/19/2025 Non-covered Recipient Entity
MARWAH INVESTMENTS CORPORATION
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252969351
Principal investigator 1 ModernaTX, Inc. $3,025.10 03/19/2025 Non-covered Recipient Entity
MARWAH INVESTMENTS CORPORATION
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252969375
Principal investigator 1 ModernaTX, Inc. $2,347.00 03/19/2025 Non-covered Recipient Entity
MARWAH INVESTMENTS CORPORATION
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252969389
Principal investigator 1 ModernaTX, Inc. $10,879.70 02/21/2025 Non-covered Recipient Entity
MARWAH INVESTMENTS CORPORATION
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252969377
Principal investigator 1 GlaxoSmithKline, LLC. $4,924.47 02/19/2025 Non-covered Recipient Entity
ACRC TRIALS
A PHASE 2 RANDOMIZED, ACTIVE-CONTROLLED, OBSERVER-BLIND STUDY TO ASSES No dispute reported 06/30/2026 1192168412
Principal investigator 1 ModernaTX, Inc. $1,387.10 02/19/2025 Non-covered Recipient Entity
MARWAH INVESTMENTS CORPORATION
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252969335
Principal investigator 1 GlaxoSmithKline, LLC. $1,417.00 02/12/2025 Non-covered Recipient Entity
MARWAH INVESTMENTS CORP DBA ACR
A PHASE III, RANDOMIZED, CONTROLLED, OBSERVER-BLIND STUDY TO EVALUATE No dispute reported 06/30/2026 1192168407
Principal investigator 1 GlaxoSmithKline, LLC. $4,233.00 02/12/2025 Non-covered Recipient Entity
MARWAH INVESTMENTS CORP DBA ACR
A PHASE III, RANDOMIZED, CONTROLLED, OBSERVER-BLIND STUDY TO EVALUATE No dispute reported 06/30/2026 1192168418
Principal investigator 1 ModernaTX, Inc. $391.30 01/29/2025 Non-covered Recipient Entity
MARWAH INVESTMENTS CORPORATION
A Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 Vaccine in Adolescents 12 to <18 Years Old to Prevent COVID-19 No dispute reported 06/30/2026 1252969319
Principal investigator 1 ModernaTX, Inc. $83,062.85 01/29/2025 Non-covered Recipient Entity
MARWAH INVESTMENTS CORPORATION
A Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 Vaccine in Adolescents 12 to <18 Years Old to Prevent COVID-19 No dispute reported 06/30/2026 1252969321
Principal investigator 1 ModernaTX, Inc. $1,400.00 01/29/2025 Non-covered Recipient Entity
MARWAH INVESTMENTS CORPORATION
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252969353
Principal investigator 1 ModernaTX, Inc. $527.15 01/29/2025 Non-covered Recipient Entity
MARWAH INVESTMENTS CORPORATION
A Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 Vaccine in Adolescents 12 to <18 Years Old to Prevent COVID-19 No dispute reported 06/30/2026 1252969387
Principal investigator 1 PFIZER INC. $776.25 01/29/2025 Non-covered Recipient Entity
Marwah Investments Corporation dba ACRC Trials
A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VACCINE CANDIDATES IN HEALTHY CHILDREN No dispute reported 06/30/2026 1228833272
Principal investigator 1 ModernaTX, Inc. $15,913.30 01/24/2025 Non-covered Recipient Entity
MARWAH INVESTMENTS CORPORATION
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252969355
Principal investigator 1 ModernaTX, Inc. $1,875.00 01/15/2025 Non-covered Recipient Entity
MARWAH INVESTMENTS CORPORATION
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252969347
Principal investigator 1 ModernaTX, Inc. $500.00 01/08/2025 Non-covered Recipient Entity
MARWAH INVESTMENTS CORPORATION
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252969349
Principal investigator 1 AstraZeneca Pharmaceuticals LP $18,000.00 01/03/2025 Non-covered Recipient Entity
ACRC TRIALS
a phase 3,global,randomized,modified double blind,placebo controlled,study to evaluate the efficacy,immunogenicity,and safety of IVX A12,a respiratory syncytial virus RSV and human metapneumovirus hMPV virus like particle VLP vaccine in adults 60 years of age and older No dispute reported 06/30/2026 1185539493